FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: opalapril who wrote ()	10/6/1999 3:51:00 PM
From: opalapril	Read Replies (1) of 75

MLNM shot up 10% or more today, but CNBC has it wrong as to the reason. Kernan claims it is the news about the deal giving MLNM access to INCY's genomic data base. It looks much more likely to me it is news of identification of a T-cell receptor re: asthma. MLNM is too expensive for my taste rights now, but this is something to think about for the future: asthma cures sell on Wall Street. go2net.newsalert.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next